Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein
Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein
复制标题
DOI：
10.1073/pnas.0306431101
复制
发表时间：
2004-03-09
影响因子：
11.1
通讯作者：
Cartier, N
中科院分区：
文献类型：
--
作者：
Asheuer, M;Pflumio, FO;Cartier, N
在啮齿类动物中，骨髓来源的细胞在成年后进入大脑。同种异体骨髓移植用于治疗遗传性中枢神经系统疾病，但人骨髓和脑内CD34(+)细胞的命运仍有待阐明。本研究表明，从脐带血或外周血中分离出的人类 CD34(+) 细胞来源的细胞在输注到非肥胖糖尿病/严重联合免疫缺陷小鼠体内后会迁移到大脑中。两种类型的 CD34(+) 衍生细胞均分化为血管周围小胶质细胞和分支小胶质细胞。输注前将基因慢病毒转移到CD34+细胞中不会改变人CD34+细胞向小胶质细胞的分化，从而允许新的转基因蛋白在这些细胞中表达。因此，CD34(+)细胞的移植可用于治疗中枢神经系统疾病。
In rodents, bone marrow-derived cells enter the brain during adult life. Allogeneic bone marrow transplantation is used to treat genetic CNS diseases, but the fate of human bone marrow and CD34(+) cells within the brain remains to be elucidated. The present study demonstrates that cells derived from human CD34(+) cells, isolated from either cord blood or peripheral blood, migrate into the brain after infusion into nonobese diabetic/severe combined immunodeficient mice. Both types of CD34(+)-derived cells differentiate into perivascular and ramified microglia. The lentiviral transfer of genes into CD34(+) cells before infusion does not modify the differentiation of human CD34(+) cells into microglia, allowing new transgenic proteins to be expressed in these cells. The transplantation of CD34(+) cells could thus be used for the treatment of CNS diseases.